Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression-Reference-Cited by-同舟云学术

Maintenance therapy with ex vivo expanded lymphokine‐activated killer cells and rituximab in patients with follicular lymphoma is safe and may delay disease progression

Published:2020-03-04 Issue:6 Volume:189 Page:1064-1073
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

López‐Díaz de Cerio Ascensión¹²³,García‐Muñoz Ricardo⁴,Pena Esther¹,Panizo Ángel²⁵,Feliu Jesús⁴,Giraldo Pilar⁶,Rodríguez‐Calvillo Mercedes⁷,Martínez‐Calle Nicolás¹^ORCID,Grande Carlos⁸,Olave María T.⁹,Andrade‐Campos Marcio¹⁰,Bandrés Eva⁷,Núñez‐Córdoba Jorge M.¹¹,Inogés Susana¹²³^ORCID,Panizo Carlos¹²^ORCID

Affiliation:

1. Cell Therapy Area and Department of Hematology Clínica Universitaria de Navarra PamplonaNavarraSpain

2. Lymphoproliferative Group Health Research Institute Navarra (IDISNA) PamplonaNavarraSpain

3. Department of Immunology and Immunotherapy Clínica Universidad de Navarra Pamplona NavarraSpain

4. Department of Hematology San Pedro Hospital Logroño La RiojaSpain

5. Department of Pathology Hospital Complex Navarre Pamplona NavarraSpain

6. Translational Research Unit Health Research Institute AragónCIBER Rare DiseasesCIBERER ZaragozaSpain

7. Department of Hematology Hospital Complex Navarre Pamplona NavarraSpain

8. Hematology Service University Hospital, 12 de Octubre MadridSpain

9. Hematology Service University Clinic Lozano Blesa ZaragozaAragónSpain

10. Hematology Service University Hospital Miguel Servet Zaragoza AragónSpain

11. Research Support Service Central Clinical Trials Unit Clínica Universidad de Navarra Instituto de Investigación Sanitaria de Navarra (IdiSNA) PamplonaNavarraSpain

Funder

Ministerio de Sanidad, Política Social e Igualdad of the Spanish Government

Publisher

Wiley

Subject

Hematology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.16474

Reference22 articles.

1. Cancer Therapy Evaluation ProgramCommon Terminology Criteria for Adverse Events Version 3.0 DCTD NCI NIH DHHS. (2006). [cited 2003 Mar 31] Available from:http://ctep.cancer.gov

2. Systemic Interleukin-2 and Adoptive Transfer of Lymphokine-Activated Killer Cells Improves Antibody-Dependent Cellular Cytotoxicity in Patients with Relapsed B-Cell Lymphoma Treated with Rituximab

3. Cytotoxic T lymphocytes for leukemia and lymphoma

4. Early Relapse of Follicular Lymphoma After Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Defines Patients at High Risk for Death: An Analysis From the National LymphoCare Study

5. Revised Response Criteria for Malignant Lymphoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Natural Killer Cells: A Promising Kit in the Adoptive Cell Therapy Toolbox;Cancers;2022-11-17

2. The Future of Natural Killer Cell Immunotherapy for B Cell Non-Hodgkin Lymphoma (B Cell NHL);Current Treatment Options in Oncology;2022-03

3. Long-term survival of a feline with non-T/B large granular lymphocyte lymphoma treated with chemotherapy and activated lymphocyte therapy;Open Veterinary Journal;2022

4. Expanding the Toolbox of Adoptive Cell Immunotherapy;Journal of Clinical Oncology;2021-05-01

5. Recent advances in cellular therapy for malignant lymphoma;Cytotherapy;2021-02